Several antiproliferative agents have been explored for use in neonatal disorders. Propranolol, a beta-blocker with antiproliferative properties, is frequently used to treat infantile hemangioma. Sirolimus and Everolimus, mTOR inhibitors, have been used experimentally to manage rare vascular anomalies and overgrowth syndromes. These agents are chosen based on their efficacy and safety profiles in neonates.
